Title | Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | S Minami S, Min S-W, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH, Elia LP, Ward ME, Mucke L, Farese RV, Gan L |
Journal | Nat Med |
Volume | 20 |
Issue | 10 |
Pagination | 1157-64 |
Date Published | 2014 Oct |
ISSN | 1546-170X |
Keywords | Alzheimer Disease, Amyloid beta-Peptides, Animals, Brain, Cognition, Disease Models, Animal, Female, Frontotemporal Lobar Degeneration, Gene Expression Regulation, Humans, Immunity, Innate, Intercellular Signaling Peptides and Proteins, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Microglia, Phagocytosis, Plaque, Amyloid, Rats, Up-Regulation |
Abstract | Haploinsufficiency of the progranulin (PGRN) gene (GRN) causes familial frontotemporal lobar degeneration (FTLD) and modulates an innate immune response in humans and in mouse models. GRN polymorphism may be linked to late-onset Alzheimer's disease (AD). However, the role of PGRN in AD pathogenesis is unknown. Here we show that PGRN inhibits amyloid β (Aβ) deposition. Selectively reducing microglial expression of PGRN in AD mouse models impaired phagocytosis, increased plaque load threefold and exacerbated cognitive deficits. Lentivirus-mediated PGRN overexpression lowered plaque load in AD mice with aggressive amyloid plaque pathology. Aβ plaque load correlated negatively with levels of hippocampal PGRN, showing the dose-dependent inhibitory effects of PGRN on plaque deposition. PGRN also protected against Aβ toxicity. Lentivirus-mediated PGRN overexpression prevented spatial memory deficits and hippocampal neuronal loss in AD mice. The protective effects of PGRN against Aβ deposition and toxicity have important therapeutic implications. We propose enhancing PGRN as a potential treatment for PGRN-deficient FTLD and AD. |
DOI | 10.1038/nm.3672 |
Alternate Journal | Nat. Med. |
PubMed ID | 25261995 |
PubMed Central ID | PMC4196723 |
Grant List | P50 AG023501 / AG / NIA NIH HHS / United States F31AG034793 / AG / NIA NIH HHS / United States 1R01AG036884 / AG / NIA NIH HHS / United States R01 AG036884 / AG / NIA NIH HHS / United States R01AG030207 / AG / NIA NIH HHS / United States F32 NS076239 / NS / NINDS NIH HHS / United States P30NS065780 / NS / NINDS NIH HHS / United States F32NS076239 / NS / NINDS NIH HHS / United States |